Quality by design in pharmaceutical analysis: Essential but underutilized

Sumit Dayane[1], Sandeep A. Wathore[2], Kishore B. Charate[3]

[1]Department of Pharmaceutical Analysis and Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India, [2]Department of Pharmaceutics, SVP College of Pharmacy, Hatta, Maharashtra, India, [3]Department of Pharmaceutics, Samarth College of Pharmacy, Deulgaon Raja, Maharashtra, India

Correspondence:
Sumit Dayane, Department of Analysis and Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
E-mail: sumitdayane@gmail.com

How to cite this article: Dayane S, Wathore SA, Charate KB. Quality by design in pharmaceutical analysis: Essential but underutilized. Innov Pharm Planet 2023;11(1):14-17.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 30-01-2023
Date of Revision: 20-02-2023
Date of Acceptance: 27-02-2023

ABSTRACT

Quality by Design (QbD) has emerged as a transformative framework in pharmaceutical analysis, offering a systematic and science-driven approach to ensure the quality and reliability of analytical methods. Rooted in the principles of quality management, QbD emphasizes understanding and controlling variability through tools, such as Quality Target Product Profile, Critical Quality Attributes, and Design of Experiments. Despite its advantages in enhancing method robustness, regulatory compliance, and cost efficiency, the adoption of QbD in pharmaceutical analysis remains limited due to challenges such as lack of expertise, high implementation costs, and resistance to change. This review explores the principles and applications of QbD in analytical method development, highlighting its role in optimizing chromatographic, dissolution, and spectroscopy techniques. In addition, it addresses the barriers to QbD implementation and identifies opportunities for advancement through education, technological innovations, and regulatory support, underscoring its potential to revolutionize quality assurance practices in the pharmaceutical industry.

Keywords: Critical quality attributes, design of experiments, pharmaceutical analysis, quality by design

Introduction

Quality by Design (QbD) is a systematic, science-driven approach to pharmaceutical development and analysis, emphasizing the intrinsic incorporation of quality into both processes and final products. Originating from quality management principles in manufacturing, QbD was introduced to the pharmaceutical sector as a proactive alternative to traditional quality control methods, which often relied heavily on end-product testing and batch-specific inspections.[1] The QbD paradigm aims to ensure that pharmaceutical products consistently meet pre-defined quality standards by focusing on a deep understanding of processes and the factors influencing them. This systematic approach not only enhances product quality but also contributes to greater efficiency and reliability in pharmaceutical development.[2]

Access this article online	
Website: https://innovationaljournals.com/index.php/ip	**e-ISSN:** 2348-7275
DOI: 10.31690/ipplanet.2023.v011i01.005	

Regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency have strongly advocated for the adoption of QbD, embedding its principles into guidelines such as the International Council for Harmonisation (ICH) Q8-Q10 series. These frameworks emphasize the identification and control of Critical Quality Attributes (CQAs) and the utilization of tools, such as risk assessments and Design of Experiments (DoE) to develop robust, reproducible processes. By adopting QbD, manufacturers can better anticipate and mitigate risks, optimize resource utilization, and align processes with regulatory requirements, fostering innovation and efficiency in pharmaceutical practices.[3]

The application of QbD in pharmaceutical analysis is particularly transformative, offering immense potential to enhance the precision, reliability, and efficiency of analytical methods. A pivotal component of QbD is the integration of the Analytical Target Profile (ATP) into analytical method development. The ATP sets clear performance criteria, ensuring that methods are designed with specific goals in mind, such as accuracy, sensitivity, and robustness. This proactive approach minimizes variability, enhances reproducibility, and significantly reduces the time and cost associated with analytical method development. Furthermore, QbD aligns seamlessly with modern technological advancements, including automation and advanced modeling software, which enhance method optimization and validation.[4]

Despite its evident advantages, the widespread adoption of QbD in pharmaceutical analysis has been limited due to several barriers. The lack of adequate expertise and specialized training remains a significant challenge, as QbD requires a deep understanding of statistical tools, risk assessment techniques, and process optimization methodologies. The high initial costs associated with implementing QbD frameworks; including training, software, and infrastructure, further deters adoption, particularly among small and medium-sized enterprises. In addition, resistance to change and a reliance on traditional quality control practices contribute to the slow integration of QbD principles into routine analytical operations.

Overcoming these challenges requires a multifaceted approach. Expanding educational initiatives and professional training programs can bridge the expertise gap, equipping professionals with the skills needed to implement QbD effectively. Regulatory agencies can play a critical role by providing clearer guidelines, incentivizing compliance, and highlighting the long-term benefits of QbD adoption. Technological advancements, such as the development of user-friendly QbD tools and software, can simplify implementation and reduce associated costs. Addressing these obstacles could unlock the full potential of QbD, making it an indispensable tool in ensuring the quality, safety, and efficacy of pharmaceutical products.

The adoption of QbD is not merely a regulatory expectation but also a strategic necessity in a rapidly evolving pharmaceutical landscape. By embedding quality into every stage of the product lifecycle, QbD not only ensures compliance with stringent regulatory standards but also enhances patient safety and satisfaction. As the industry continues to face challenges such as increasing complexity in drug formulations and heightened regulatory scrutiny, QbD stands out as a robust, forward-thinking approach that can drive innovation while maintaining the highest quality standards.

Principles and Framework of QbD in Pharmaceutical Analysis

QbD is built on a robust framework that integrates scientific understanding and risk management to ensure analytical methods meet pre-defined quality requirements. The foundation of QbD lies in its key elements: Quality Target Product Profile (QTPP), CQAs, and the application of DoE. These elements guide the systematic development of analytical methods by identifying and controlling variables that influence performance and quality.

The QTPP defines the desired characteristics of the pharmaceutical product; serving as a foundation for identifying CQAs – specific attributes that must be maintained within acceptable limits to ensure product quality. For analytical methods, these attributes often include parameters such as specificity, accuracy, precision, and robustness. DoE is employed to optimize the method by studying the effects of multiple variables simultaneously, enabling efficient identification of critical method parameters and their optimal operating ranges.[5]

Risk assessment tools such as Failure Mode and Effect Analysis (FMEA) play a pivotal role in QbD by prioritizing potential risks in the analytical process. This proactive approach allows for the mitigation of risks early in development, ensuring the reliability and reproducibility of the analytical method. In addition, the ATP aligns method performance with QbD principles, providing a clear benchmark for evaluating the effectiveness of the method during its lifecycle.[6] The important tools and key elements are summarized in Table 1.

This structured approach not only enhances the scientific rigor of pharmaceutical analysis but also fosters flexibility and innovation, enabling the development of robust methods tailored to evolving regulatory and industrial needs.

Applications of QbD in Analytical Method Development

The application of QbD principles in analytical method development has revolutionized traditional practices, offering a structured, science-driven approach to achieve reliable and robust methods. By integrating key QbD elements such as CQAs and DoE, analysts can develop optimized methods tailored to meet specific performance criteria.[8]

Table 1: Key elements and tools in quality by design (QbD) framework for pharmaceutical analysis[7]

Key element/tool	Definition	Role in QbD
Quality Target Product Profile (QTPP)	A summary of the desired quality characteristics of the product.	Defines the objectives for method development and sets the basis for identifying CQAs.
Critical Quality Attributes (CQAs)	Specific attributes are critical to product quality, such as accuracy and precision.	Guides the identification and control of variables affecting the analytical method.
Design of Experiments (DoE)	A statistical tool for studying the effects of multiple variables simultaneously.	Optimizes method parameters and enhances robustness through efficient experimentation.
Failure Mode and Effect Analysis (FMEA)	A risk assessment tool to identify and mitigate potential risks in processes.	Prioritizes and addresses critical risks to improve method reliability.
Analytical Target Profile (ATP)	A pre-defined set of performance criteria for analytical methods.	Ensures alignment of analytical methods with desired quality outcomes.

One prominent example of QbD-based method development is in chromatographic techniques, such as High-Performance Liquid Chromatography (HPLC). Using DoE, analysts can evaluate the effects of variables, such as mobile phase composition, flow rate, and column temperature on method performance. This approach enables the identification of an optimal method design space, ensuring precision and reproducibility even under variable conditions.[9] Similarly, in dissolution testing, QbD principles help optimize factors, such as agitation speed and dissolution medium, leading to robust methods that accurately simulate *in vivo* drug release profiles. Spectroscopy methods, including UV-Vis and FTIR, also benefit from QbD by ensuring consistency in spectral measurements through careful calibration and validation of equipment and parameters.[10]

The advantages of QbD in analytical method development are numerous. First, it ensures methods are robust and less sensitive to minor changes in operational variables, reducing the likelihood of failures. Second, the systematic use of DoE minimizes experimental runs, saving time and resources while yielding comprehensive insights into method behavior. Third, methods developed under the QbD framework are inherently compliant with regulatory expectations, as they emphasize a deep understanding of critical parameters and risks.[11]

Several case studies underscore the successful implementation of QbD in analytical development. For instance, a QbD-driven approach was used to develop a gradient HPLC method for determining impurities in a pharmaceutical formulation. Through DoE, the critical method parameters were optimized, leading to a method that met all regulatory requirements for specificity, linearity, and robustness. Another example is the application of QbD in optimizing a dissolution method for an extended-release tablet, which improved method reproducibility and reduced variability across different batches.[12]

By leveraging QbD principles, analytical development has moved from being reactive and trial-based to proactive and knowledge-driven. This shift not only enhances the quality and efficiency of pharmaceutical processes but also fosters innovation in method development, ensuring the consistent delivery of high-quality products.

Challenges and Opportunities in Implementing QbD

The implementation of QbD in pharmaceutical analysis, while transformative, is not without its challenges. One of the most significant barriers to adoption is the lack of expertise among industry professionals. QbD requires a deep understanding of statistical tools, process optimization, and risk assessment, skills that are not always readily available. In addition, the high initial costs of implementing QbD frameworks; including training, software, and infrastructure, deter many organizations. Resistance to change, a common obstacle in traditional industries, further impedes the transition to QbD, as stakeholders may prefer established, less complex methodologies.[13]

Despite these barriers, there are substantial opportunities to enhance QbD adoption. Educational programs and workshops can equip professionals with the necessary skills to apply QbD principles effectively. Advancements in analytical tools, such as automated platforms and sophisticated modeling software, can simplify QbD processes [Table 2], making them more accessible and efficient. Regulatory agencies are increasingly advocating for QbD, offering guidelines and incentives that align with its principles. This regulatory support not only encourages adoption but also assures organizations of the long-term benefits of compliance with QbD standards.[14]

Table 2: Integration of quality by design (QbD) with emerging technologies in pharmaceutical analysis[16,17]

Aspect	Description	Benefits
Role of Advanced Technologies in Enhancing QbD Implementation	Advanced technologies, such as automation, machine learning (ML), and artificial intelligence (AI) can streamline pharmaceutical process design and optimization within the QbD framework.	- Efficient process design. - Faster optimization. - Minimized human error. - Improved prediction of process outcomes.
Smart Manufacturing and Real-Time Monitoring	Real-time data acquisition and continuous process monitoring enable dynamic control of manufacturing processes, ensuring adherence to QbD principles.	- Enhanced process control. - Immediate corrective actions. - Improved product consistency and quality. - Reduced production downtime.
Application in Biopharmaceuticals and Complex Formulations	QbD principles can be applied to biopharmaceuticals, biologics, and gene therapies to maintain product consistency, quality, and ensure regulatory compliance.	- Ensures reproducibility in complex formulations. - Improves yield and efficiency in biopharmaceutical production. - Supports regulatory approval processes.
Synergy between QbD and Digitalization	The digitalization of pharmaceutical manufacturing through IoT and Big Data enables real-time insights and more precise adjustments to pharmaceutical processes.	- Better data-driven decision-making. - Real-time monitoring for continuous improvement. - Enhanced adaptability to process fluctuations. - Facilitates predictive maintenance.

The future prospects of QbD in pharmaceutical analysis are promising. As the industry evolves, the wider adoption of QbD can lead to significant advancements in product quality and process efficiency. Analytical methods developed under QbD frameworks are inherently robust, ensuring consistent performance even under variable conditions.[15] Furthermore, the proactive risk management and data-driven nature of QbD streamline regulatory processes, reducing the time and resources required for method validation and approval. With continued emphasis on education, technological integration, and regulatory alignment, QbD has the potential to redefine the standards of quality assurance in pharmaceutical analysis.

Conclusion

QbD offers a transformative, science-driven approach to pharmaceutical analysis, ensuring robust and reproducible methods that meet regulatory standards. By integrating tools, such as QTPP, CQAs, and DoE, QbD enhances method performance and reduces variability. Despite its advantages, challenges such as high costs and limited expertise hinder widespread adoption. Addressing these barriers through education, technology, and regulatory support can unlock QbD's full potential, advancing quality assurance in pharmaceutical practices.

References

1. Sonawane C, Deore S, Bendale A. Analytical method development and validation of Ramipril and Candesartan cillexetil in synthetic mixture. Innov Pharm Pharmacother 2020;8:14-20.
2. Jain S. Quality by design (QBD): A comprehensive understanding of implementation and challenges in pharmaceuticals development. Int J Pharm Pharm Sci 2014;6:29-35.
3. Jain P, Bodhkhe S, Agrawal K, Salunke U. Active Enatiomeric form of Pregabalin based on sole and coupled chromatography methods. Pharm Methods 2022;13:26-39.
4. Junker B, Zablackis E, Verch T, Schofield T, Douette P. Quality-by-Design: As related to analytical concepts, control and qualification. In: Vaccine Analysis: Strategies, Principles Control. Berlin, Heidelberg: Springer; 2014. p. 479-520.
5. Patil AS, Pethe AM. Quality by Design (QbD): A new concept for development of quality pharmaceuticals. Int J Pharm Qual Assur 2013;4:13-9.
6. Shah R, Nagar A, Shirkhedkar A, Bendale A. Combined and comparative analytical studies with stability studies and validation for estimation of Prenoxdiazine HCl in pharmaceutical dosage form. Fut J Pharm Sci 2023;9:1-11.
7. Taticek R, Liu J. Definitions and scope of key elements of QbD. In: Quality by Design for Biopharmaceutical Drug Product Development. Berlin: Springer; 2015. p. 31-46.
8. Lloyd DK, Bergum J. Application of quality by design (QbD) to the development and validation of analytical methods. In: Specification of Drug Substances and Products. Amsterdam: Elsevier; 2014. p. 29-72.
9. Thakur D, Kaur A, Sharma S. Application of QbD based approach in method development of RP-HPLC for simultaneous estimation of antidiabetic drugs in pharmaceutical dosage form. J Pharm Invest 2017;47:229-39.
10. Patadia R, Vora C, Mittal K, Mashru RC. Quality by design empowered development and optimisation of time-controlled pulsatile release platform formulation employing compression coating technology. AAPS Pharmscitech 2017;18:1213-27.
11. Schweitzer M, Pohl M, Hanna-Brown M, Nethercote P, Borman P, Hansen G, *et al*. Implications and opportunities of applying QbD principles to analytical measurements. Pharm Tech 2010;34:52-9.
12. Sandhu PS, Beg S, Katare OP, Singh B. QbD-driven development and validation of a HPLC method for estimation of tamoxifen citrate with improved performance. J Chromatogr Sci 20116;54:1373-84.
13. Torres M. Challenges in implementing quality by design. Bioprocess Int 2015;13:6.
14. Varu RK, Khanna A. Opportunities and challenges to implementing Quality by Design approach in generic drug development. J Generic Med 2010;7: 60-73.
15. Shinde SU, Bardiya RS, Jain PS. Comparison of acid degradant product with metabolic pathway of remogliflozin etabonate in developed and validated RP-HPTLC method. Indian Drugs 2022;59:46-53.
16. Das P, Maity A. Analytical quality by design (AQbD): A new horizon for robust analytics in pharmaceutical process and automation. Int J Pharm Drug Anal 2017;5:324-37.
17. Wu H, Khan MA. Quality-by-Design (QbD): An integrated process analytical technology (PAT) approach for real-time monitoring and mapping the state of a pharmaceutical coprecipitation process. J Pharm Sci 2010;99:1516-34.